Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Purpose To evaluate Hyperthermic-Intra-Vesical Chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with High-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who fail BCG therapy or are contraindicated to BCG. Methods Between June...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Laure Doisy, Arnaud Cimier, Aurélien Adypagavane, Jochen Walz, Thibault Marquette, Thomas Maubon, Stanislas Rybikowski, Sami Fakhfakh, Kevin Loverde, Nicolas Mottet, Jacques Irani, Eric Lechevallier, Dominique Rossi, Gwenaelle Gravis, Géraldine Pignot
Format: article
Langue:EN
Publié: Taylor & Francis Group 2021
Sujets:
bladder cancer
bcg-refractory
cystectomy
chemohyperthermia
recurrence
progression
Medical technology
R855-855.5
Accès en ligne:https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df2

Documents similaires